An observational study in Anthrax, sponsored by Qin Ning. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Qin Ning · Observational
This study is a clinical, multi-center, retrospective, case-control study. Patients clinically diagnosed with severe anthrax who meet the inclusion and exclusion criteria will be included in this study for analysis. Respiratory, circulation, nerve and other vital signs of patients with severe anthrax during hospitalization were recorded, and clinical data such as blood routine, blood biochemistry, coagulation function, myocardial injury, therapeutic drug use, and survival time of patients were recorded, as well as the survival situation of patients 28 days and 90 days after discharge.
75 studies on the registry are indexed under Anthrax; 12 are open to participants now.
This study's planned enrollment of 80 is below the median of 99 across 16 observational studies indexed under Anthrax.
Browse Anthrax studies →Qin Ning is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with severe anthrax
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There are other conditions that affect short-term survival.
Patients who survived in 28 days/90 days
Patients who survived in 28 days/90 days
mortality rates of severe anthrax
mortality rates of severe anthrax
Time frame: 28 days and 90 days
incidence of complications
To evaluate the incidence of respiratory, circulatory, neurological, digestive, coagulation and other complications of severe anthrax
Time frame: in hospital
Peripheral blood biomarkers associated with 28-day and 90-day mortality
Peripheral blood biomarkers associated with 28-day and 90-day mortality
Time frame: 28 days and 90 days
the improvement in 28-day and 90-day mortality with treatment for severe anthrax
the improvement in 28-day and 90-day mortality with treatment for severe anthrax
Time frame: 28 days and 90 days
Started Mar 2024 (actual). Primary completion is estimated for Aug 2024, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qin Ning